User:Benediktusrayo/Phenome-wide association study

Methods
PheWAS initially started from the growing use of EMR (electronic medical record) for clinical practice and patient care. One of the main components of EMR system is the International Classification of Disease version 9-CM (ICD9) codes, used as a tool for medical billing record. This system includes information of 14,000 diseases binned into different hierarchy codes. These phenotypic information is the basis of the PheWAS study, which associates a genetic variant (or a combination of variants) with a wide range of phenotypes.

Most common PheWAS studies would divide its cohort into two groups: individuals who did not have a specific ICD9 code are treated as “controls” while individuals who has an ICD9 code associated with them are considered “cases”. Starting from the given genetic variant, a PheWAS would systematically perform genetic variant (typically a SNP) analysis to identify how a particular genotype would be associated to a phenotype. From the variant data, PheWAS calculates their genotype distribution and the chi-squared distribution, followed by Fisher's exact test to calculate the P-value, identifying how relevant a genotype would be to a certain phenotype of interest from the EMR. Often times, Bonferroni correction is applied to take into consideration the multiple comparisons done while calculating the P-value.

Proof of Concept
The first study of PheWAS was done on 6000 European-American population with 5 SNPs of interest picked for validation: rs1333049, rs2200733, rs3135388, rs6457620, and rs1333049. Quality control was done by examining marker and sample genotyping efficiency, allele frequency calculations, and Hardy-Weinberg equilibrium tests.

This initial PheWAS aim to examine the impact of genetic variants across various phenotypes. Since the ICD9 was not specifically designed for research purposes, this PheWAS devised a new way to simplify the code for genetic studies. Specifically, three modifications were made to the ICD9:


 * 1) First, they combine three-digit codes from diseases that arise from the same or similar origin. For example, tuberculosis has three subtypes and all three are merged to one case group of 010.
 * 2) Secondly, the addition of a fourth digit identifier for phenotypes that are clinically distinct, but are categorized to be the same. An instance would be Type I and Type II diabetes, two clinically distinct phenotypes that fall under ICD9 code of ‘250’. An additional fourth digit will be added to differentiate the two phenotypes.
 * 3) Lastly, codes that are deemed to be useless for genotypic-phenotypic analysis are ignored. Cases such as foreign object contamination or non-specific symptoms / non-specific laboratory result would fall under this category.

As one example of its successes, this PheWAS show evidence of strong association between rs3135388 and MS, which was a previously studied association. Twenty-two other diseases also demonstrated significant associations with P < 0.05.

Pleiotropy Study
One of the main advantages of the PheWAS study is its potential to identify genomic variants with pleiotropic properties. Understanding cross-phenotype (CP) associations, where one genetic variation can affect two or more independent phenotypes, is the key to understanding the pleiotropic effect. The pleiotropic effect study was done by first obtaining the summary of genotype and phenotype data from the Population Architecture using Genomics and Epidemiology (PAGE) study sites. After several quality control and data organization steps, either the standard logistic or linear regression analysis is performed depending on the phenotypic information. Subsequently, all continuous phenotypes are log-transformed before the association between the SNPs and the transformed phenotypes is finally calculated.

Generally, there are two types of results from a PheWAS study:


 * A result can be considered 'expected' if a genotype-phenotype association has previously been observed and reported. These cases can validate the legitimacy of PheWAS and act as a positive control. For instance, diabetes-related phenotypes like hyperinsulinemia, obesity, and fasting glucose level are shown to be associated with phenotypes of type II diabetes from PheWAS.
 * A novel result would be more of interest since it demonstrates the power of PheWAS for discovering new associations that have not been reported before. If two disease phenotypes are not previously-known as related and a single SNP is shown to give rise to these two phenotypes, it is a good indication that a pleiotropic effect is present. An example of this pleiotropic discovery is a SNP that's already known to be associated with diabetes turns out to also be significantly associated with arthritis.

Even though novel associations between phenotype is discovered, further biological studies is necessary to determine whether it actually reflects the system.

Drug Response Variability
A PheWAS has also successfully highlights discrepancies in drug response among individuals. A quantitative PheWAS study was done to identify variation in thiopurine response. The EMR stores quantitative value of IBD patient's TPMT (thiopurine S-methyltransferase) activity, which then allow the researchers to split the patients it into three categories: low TPMTa, normal TPMTa, and very high TPMTa. It was found that cohorts with very high TPMTa level are associated with diabetes mellitus and iron-deficiency anemia, which further shows that thiopurine therapy are three times more likely to fail in patients with very high TPMTa. Performing thiopurine therapy on patient with very high TPMTa level may increase the frequency of anemia episode. This PheWAS finding may further the progress of personalized treatment, based on patient's measurement. Instead of treating IBD patients with the conventional thiopurine treatment, patient may benefit more from more intensive therapy or other approaches.

Clinical Trial
A clinical test has been done by utilizing PheWAS on HIV patients, obtained from the AIDS Clinical Trial Group (ACTG) datasets from 27 different laboratories. Identifying accuracy between PheWAS and clinical trials is important before pushing PheWAS further for making clinical decisions. Forty-seven percent of the previously-reported associations were successfully reproduced in this study, demonstrating this PheWAS' capability for working with clinical data. Additionally, several pleiotropic effects were discovered using this clinical data. Specifically, a block of SNPs on chromosome 7 were associated to both LDL-C phenotypes and the total cholesterol level according to this study. For clinical relevance, more research need to be done to validate the pleiotropic effect obtained from PheWAS.

Limitations
Despite the promising potentials, PheWAS has some potential limitations:


 * Statistical limitation: Bonferroni correction is potentially not addressing the entirety of the dataset due to the lack of independence across many phenotypes.
 * ICD9-notation limitation: not every phenotype can be represented in an ICD9 code. One ICD9 code can have a high variability, making it impossible to assess the validity of phenotypes that are coded to ICD9 for all the patients.
 * Association limitation: upon performing a regression analysis for variant-phenotype association, covariates like age and sex may contribute in the resulting phenotypes. A simple regression analysis fail to take into account these covariates. Therefore, a follow-up phenotype-specific validation need to be done, which ideally would include information about the patient's covariates.